Figure 1.

The effect of metformin on vessel co-option, recurrence, and extrahepatic metastases. (a) Represents the percentage of patients with vessel co-option (RHGP), angiogenic (DHGP), or mixed (RHGP and DHGP) lesions according to the administration of metformin. (b) Represents the association between metformin administration by CRCLM patients and the development of recurrent tumours after hepatectomy. (c) Shows the correlation between the usage of metformin by CRCLM patients and the development of extrahepatic metastases after surgical resection. Chi-square test was used to compare the categorical variables.